“Although the vast majority of biotech stocks are losing money, a handful of these profitable drug developers are valued at levels that make them absolute bargains,” observes the author of today’s article. He proceeds to highlight what he sees as the three biggest bargains in the entire biotech industry right now, including one firm he describes as “the perfect example of a high-growth and profitable biotech stock that’s getting far too little respect on Wall Street.” For more, CLICK HERE.